Publications
5674 Results
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il) Abstract # 12090 Poster Bd # 110
- Year
- 2025
Depression in Patients with Advanced Prostate Cancer in SWOG Advanced Cancer Clinical Trials
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster, Abstract # 11076 Poster Bd # 415
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1417CD
Longitudinal changes in credit status for newly diagnosed metastatic colorectal cancer patients
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster, Abstract # 1544 Poster Bd # 297
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S2108CD
Successful implementation of a cluster randomized controlled trial (RCT) comparing an educationally enhanced genomic tumor board (EGTB) intervention to usual practice to increase evidence-based genome-informed therapy (S2108CD, NCT# 05455606)
- Journal / Conference
- JCO Oncology Advances Jun 13;2(1):e2500021
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID40546794
- PMC
- PMC12178165
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies
- Journal / Conference
- ESMO (Berlin, Germany 17-21 October 2025)
- Year
- 2025
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
Neoadjuvant versus adjuvant pembrolizumab for resectable Stage III-IV melanoma (SWOG S1801)
- Journal / Conference
- Cancer Communications Aug;45(8):976-986
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID40402690
- PMC
- PMC12365539
- Study Number(s)
- S1609
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Impact of Sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
The prognostic impact of SLFN11 gene expression in metastatic colorectal cancer (mCRC) (Alliance)
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer, CALGB (Alliance)/SWOG 80405 and Real-World Data
- Journal / Conference
- ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405